Hemp Extract Formulation for Controlled Psychoactive Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of safe and targeted hemp products with sufficient scientific data to support their efficacy for treating medical conditions in humans and animals, despite claims of health benefits from traditional pharmacological agents.
Innovation Solution
Development of hemp extracts with specific concentrations of cannabidiol, cannabidiolic acid, cannabigerol, and other cannabinoids, formulated with carriers and additives, for treating chronic pain, anxiety, and inflammatory bowel disease, among other conditions, ensuring minimal psychoactive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hemp products with broad spectrum cannabinoids are used to provide therapeutic benefits, then health benefits including analgesic, anti-anxiety, and anti-inflammatory effects are improved, but psychoactive effects and safety concerns worsen
Solution Approach 1:
The patent applies local quality by creating distinct cannabinoid profile zones within the hemp product spectrum. Specifically, it defines products with targeted cannabinoid ratios (e.g., CBD-dominant formulations with specific THC limits) that provide localized therapeutic effects in specific body systems or conditions without producing widespread psychoactive effects. This allows different regions of the product line to serve different therapeutic needs while maintaining safety profiles.
Solution Approach 2:
The patent utilizes parameter changes by precisely controlling and varying cannabinoid concentration parameters (THC content, CBD content, and their ratios) to achieve desired therapeutic effects while minimizing psychoactive properties. By adjusting these chemical parameters within specific ranges, the patent transforms hemp products from uniformly psychoactive to selectively therapeutic, enabling dosage-formulation strategies that optimize efficacy-safety balance.
2Reliability
If traditional pharmacological agents are used for treatment, then established efficacy is achieved, but safety and side effect profiles worsen
Solution Approach 1:
The patent employs cannabinoids as intermediary substances that mediate between traditional pharmacological approaches and natural plant-based treatments. These cannabinoid compounds act as bioactive intermediaries that can modulate physiological processes with potentially fewer side effects than conventional drugs, while still providing reliable therapeutic effects. The intermediary role of cannabinoids bridges the gap between efficacy and safety by offering an alternative mechanism of action.
3Quantity of substance
If hemp products with higher cannabinoid concentrations are formulated to enhance therapeutic effects, then treatment potency is improved, but psychoactive effects and safety concerns worsen
Solution Approach 1:
The patent applies parameter changes by establishing specific concentration thresholds and ratios (e.g., THC below certain levels while maintaining CBD at therapeutic levels) that decouple therapeutic potency from psychoactive effects. This allows formulation of high-potency hemp products where the quantity of active cannabinoid substances is optimized for efficacy while chemical composition parameters are controlled to prevent psychoactivity.
Solution Approach 2:
The patent segments the cannabinoid spectrum into functionally distinct categories (psychoactive vs. non-psychoactive cannabinoids) and formulates products that selectively concentrate beneficial segments (CBD, CBC, CBG) while excluding or limiting harmful segments (THC above threshold levels). This segmentation strategy enables high cannabinoid concentration formulations that target therapeutic needs without producing unwanted psychoactive effects.
Data Source
AI summary
This disclosure relates to non-naturally occurring hemp extracts comprising cannabinoids and related treatment methods.